When do biologic drug patents expire and when will biosimilars launch?

US Patent 10,478,394: What Does It Claim for Topical Anakinra Gel Methods in Diabetic Chronic Wounds, and How Strong Is the U.S. Patent Estate?

Executive summary: US 10,478,394 is a method claim set aimed at topical, wound-facing delivery of an anakinra (therapeutic protein, SEQ ID NO: 26) gel to promote healing of chronic wounds in diabetic subjects, with narrower dependent claims for diabetic ulcers, topical application, and dressing workflows. The patent landscape around it in the U.S. splits into (1) earlier anakinra formulation and topical delivery claims, (2) diabetic wound and inflammation-based biologic gel/biomaterial claims, (3) growth factor adjunct method claims (platelet-derived growth factor and becaplermin), and (4) generic and biosimilar freedom-to-operate risks driven by whether the claimed “gel comprising anakinra consisting of SEQ ID NO: 26” and the one-step dressing workflow are meaningfully differentiating. The core infringement risk hinges on sequencing fidelity (SEQ ID NO: 26), the “consisting of” protein boundary, and whether a competing gel is a gel “administered to the chronic wound” as claimed, rather than systemically delivered or delivered through a device that changes the treatment “one step” characterization.

What patents protect topical anakinra gel methods for diabetic chronic wound healing in the U.S.?

Short answer: The protection centers on method-of-treatment using topical anakinra as the active therapeutic protein in a gel to heal chronic diabetic wounds. The strongest claim leverage is Claim 1’s requirement that the gel includes a therapeutic protein “consisting of the sequence provided in SEQ ID NO: 26 (anakinra),” and that the administration is to the chronic wound in a diabetic subject. Dependent claims tighten the wound type (diabetic ulcer), administration modality (topical), and workflow (wound dressing applied, including adhesive bandage and “achieved in one step”).

Claim scope and enforceability signals in US 10,478,394

Active ingredient boundary: Claim 1 uses a “therapeutic agent consisting of a therapeutic protein consisting of SEQ ID NO: 26 (anakinra).” Two “consisting of” boundaries usually aim to exclude:
1. proteins not matching SEQ ID NO: 26, and
2. therapeutic agents that are not limited to the protein described, depending on how the transition language is construed.
Route and target: The claim requires administration “to the chronic wound.” This supports direct infringement theories for products designed for topical wound contact rather than systemic use.
Disease and indication nexus: “Chronic wound in a diabetic subject” narrows the patient population and supports method claim enforceability when evidence shows diabetic status.
Biological mechanism breadth is not required: While anakinra is an IL-1 pathway blocker, the claim does not require a specific mechanistic biomarker. The proof burden typically shifts to wound-healing outcomes and administration practices.

How broad are the dependent claims?

Claim 2 (diabetic ulcer): narrows from any diabetic chronic wound to diabetic ulcer. If a competitor targets diabetic foot ulcer specifically, Claim 2 can still be implicated, but if it targets another diabetic chronic wound phenotype, only Claim 1 may be asserted.
Claim 3 (topically administering): sets route specificity. If a competing product is delivered via an implant or device but still results in topical administration to the wound, the legal question becomes whether it is “topical administering” in claim construction.
Claims 4-6 (wound dressing, adhesive bandage, one-step): adds product-workflow features that can be strong differentiators. Many commercial wound-care workflows use gels plus dressings. The critical question is whether competing “one-step” systems are marketed and used as a single integrated application, or as sequential steps.

Claim 7 (adjunct growth factor therapy)

Claim 7 adds method combinations with platelet-derived growth factor and/or becaplermin. This expands infringement theory for clinicians using anakinra gel plus these adjuncts. It also raises design-around options: a competitor could avoid combination therapy patterns, but that does not avoid Claim 1 unless the adjunct element becomes a required limitation for infringement of Claim 7.

When does US Patent 10,478,394 lose exclusivity in the U.S., and what does that mean for generic entry timing?

Short answer: The enforceable term of a U.S. utility patent runs 20 years from the earliest effective non-provisional filing date, adjusted for Patent Term Adjustment (PTA) and any Patent Term Extension (PTE) if applicable (none is typical for method-of-use topical biologic gel patents). The key decision point for generic or biosimilar entry is whether the product would infringe claims during the life of the patent or whether it can launch with design-around before expiration.

Where timeline risk typically concentrates for patents like this

Biosimilar/generic entry to topical anakinra: Anakinra itself is an approved biologic drug substance (elsewhere marketed for systemic use). For wound-healing topical gels, the regulatory and commercial path may be an NDA or 505(b)(2) using a known biologic active. Even if FDA approval exists, patent expiration drives enforceability.
Filing-to-expiration uncertainty: Without the patent’s priority data and PTA/PT extension figures, an exact expiration date cannot be stated from the claim text alone. What matters operationally is that patent life is usually shorter than the typical commercial cycle for diabetic wound products and adjunct combination regimens.

Actionable timing lens

If a competitor files an early development pathway (e.g., reformulation to avoid “consisting of SEQ ID NO: 26” constraints or to recharacterize delivery as a different device application), it may not need to wait for the patent to expire.
If a competitor uses anakinra (identical sequence) in a wound gel with comparable topical delivery, the timing analysis becomes a question of design-around vs. waiting for expiration.

What claim elements are most likely to be litigated in infringement under US 10,478,394?

Short answer: The likely litigation focal points are (1) whether the therapeutic protein matches SEQ ID NO: 26 under a “consisting of” construction, (2) whether the product is a “gel” administered “to the chronic wound,” (3) whether the administration is “topical,” and (4) whether the dressing workflow meets the “one step” limitation in Claims 5-6.

Protein sequence boundary: SEQ ID NO: 26 and “consisting of”

Direct infringement theory: A plaintiff can argue that a competitor’s protein matches anakinra’s sequence (SEQ ID NO: 26) and that the product contains anakinra as the therapeutic agent consistent with the claim’s “consisting of” language.
Defense theory: A defendant may argue that its protein is not within the claim because it includes additional therapeutic agents or modifications that are argued to fall outside “consisting of” the specified therapeutic protein. The practical battleground often becomes analytical characterization of the therapeutic protein and formulation composition.

“Gel comprising” vs. device-mediated delivery

Many wound-care products use:
- a gel as a carrier,
- an alginate or hydrocolloid dressing,
- an adhesive bandage interface.
The question is whether the commercial product is, in claim terms, a “gel” administered to the chronic wound, not merely a dressing that includes a coating or loading.

“One step” application workflow

If a competitor sells a kit used in two separate application events (apply gel, then apply dressing), it may argue non-infringement of Claim 5. Claim 4’s broader “further comprising applying a wound dressing” is easier to meet than Claim 5’s narrower “administering and applying are achieved in one step.”

Which companies are challenging patents like US 10,478,394 in diabetic wound biologic delivery, and how do Paragraph IV-type risks differ for method claims?

Short answer: Method claims like these are typically asserted through patent litigation against product launch rather than Orange Book Paragraph IV certification dynamics unless the patent is listed in the Orange Book for an FDA-approved drug with the claimed method. The business risk is still “launch risk,” but the procedural mechanism may be declaratory judgment, injunctive action, or settlement conditioned on non-infringing labeling and marketing.

Why Orange Book Paragraph IV is often less direct for this fact pattern

US 10,478,394 is a method claim anchored to therapeutic use and topical administration. Orange Book listing is often limited to patents that claim the drug product or use. If the patent is not listed for a specific FDA reference listed drug (RLD) or for the specific approved product, the Paragraph IV framework may not apply cleanly.
Even if Orange Book-listed, method claims can be asserted against labeling and promotional instructions, not only the dosage form.

Practical litigation posture

A typical defendant strategy is to argue non-infringement by:
- using a different protein sequence,
- using a different delivery system not described as “gel,”
- avoiding the “one step” dressing workflow,
- limiting indications such that diabetic ulcers are not the labeled use, while still using off-label in the real world.
A typical plaintiff strategy is to focus on evidence of actual use in the claimed patient population and administration modality, plus product composition and labeling that encourages the claimed method.

(No company-specific challenge list can be provided from the claim text alone. Company names require patent numbers, litigation dockets, or Orange Book listing data.)

What is the Orange Book status of US 10,478,394, and does that affect enforceability for gel-based anakinra wound therapies?

Short answer: Orange Book status is determinative of whether FDA submission certifications and regulatory triggers map to this patent, but claim enforceability itself exists regardless of listing once jurisdiction and infringement proof are established.

How Orange Book listing typically changes the business playbook

If listed as a method-of-use patent: it can create launch leverage via certification disputes, often accelerating settlement timelines.
If not listed: enforcement shifts to civil patent litigation timelines and potential state law or federal Lanham Act labeling disputes, depending on marketing facts.

(Orange Book listing status cannot be stated from the claim text alone.)

How strong is the patent estate for anakinra in wound-healing gel formulations around US 10,478,394?

Short answer: The strength is claim-construction dependent. The combination of “consisting of” protein sequence limitation plus topical administration and dressing workflow can create a narrower but higher-specificity scope. Strength is reduced if competitors can plausibly show that their therapeutic protein formulation deviates from SEQ ID NO: 26 boundaries or that their delivery is not a gel or not administered as claimed.

Estate strength drivers

Whether there are complementary claims in the same family (composition of matter, formulation, manufacturing methods, kit systems).
Whether other families cover:
- topical anakinra gel composition ranges and excipients,
- anakinra stabilization in topical gel matrices,
- wound dressing-loaded biologic systems.
Whether dependent claims create fallback positions that still capture close variants (e.g., dressing applied but not “one step”).

Key design-around pressure points

Reformulate to change the protein agent from SEQ ID NO: 26 to a different IL-1 inhibitor or engineered analog outside the sequence.
Deliver via a device or dressing that is argued not to be a “gel administered to the chronic wound.”
Use a clinical workflow that is marketed and used as sequential application, not “one step.”

What formulations are protected by US 10,478,394, and what excipient or carrier substitutions are likely non-infringing?

Short answer: The independent claim requires a gel “comprising” an anakinra protein with the specified sequence. The claim text does not recite specific excipients. That means many excipient swaps likely remain within the “gel comprising” limitation so long as the therapeutic agent limitation is met.

Likely scope of “gel”

Because “gel” is not defined in the claim excerpt, courts typically construe it in view of the specification and ordinary meaning. A competitor can attempt to avoid “gel” by using:

a liquid solution applied to the wound,
a non-gel particulate matrix,
a dressing with release from a scaffold that is argued to be not a gel carrier.

Therapeutic protein “consisting of” is more constraining than excipients

Even if excipients change, the sequence-specific protein requirement is the most likely gatekeeper. If a competitor uses identical anakinra sequence, excipient changes may not provide a safe harbor.

What method-of-use patents in diabetic wound biologic delivery could overlap US 10,478,394?

Short answer: Overlap risk is typically highest for method-of-treatment patents that combine:

diabetic chronic wound indication,
topical delivery of anakinra or an IL-1 axis inhibitor,
wound dressing adjunct steps,
and sometimes combination with growth factors like becaplermin or PDGF.

Why Claim 7 broadens overlap

Claim 7 explicitly references adding platelet-derived growth factor and/or becaplermin. This is a direct invitation to method overlap arguments in litigation where clinicians or product instructions use those adjuncts.

What overlaps don’t capture

If another patent covers systemic delivery, or uses a different therapeutic protein (even if functionally similar), it may not overlap on claim elements. Non-matching “sequence” boundaries are often dispositive for proteins where “consisting of” appears.

How does US 10,478,394 compare with prior and adjacent patent strategies for chronic diabetic wound healing?

Short answer: US 10,478,394 is closer to “specific topical protein-in-gel therapy” than to platform claims covering general wound gels without specific biologics or without the diabetic-specific method anchor.

Comparison categories

General diabetic wound gels without a specific therapeutic protein sequence: often broader but less enforceable against biologic sequence-targeted competitors.
Device-based biologic delivery (sprays, scaffolds, membranes): may avoid “gel” but risk capture if the device results in gel administration to the wound.
General IL-1 inhibitor use in wounds: may overlap if it includes diabetic chronic wounds and topical administration with anakinra.
Combination therapy patents: likely overlap due to Claim 7’s explicit adjunct references.

What patent litigation affects US 10,478,394 and related anakinra wound gel claims?

Short answer: Litigation status and docket-level facts cannot be stated from the claim text alone. Litigation risk is normally evaluated by checking:

federal district court filings mentioning the patent number,
PTAB inter partes review or post-grant review challenging validity,
and whether settlements include label or product-use restrictions.

(No litigation dossier references can be produced from the information provided.)

What generic entry risks exist for topical anakinra gels after US 10,478,394, and what design barriers protect the niche?

Short answer: “Generic entry” for a biologic protein is more accurately framed as:

biosimilar-like risks for the therapeutic protein component (sequence-identical anakinra),
and follow-on competition for the gel formulation and delivery/dressing workflow.

The largest barrier is whether competitors can meet the claim’s specific therapeutic protein sequence requirement and still launch a gel that infringes. A meaningful design barrier also comes from the method’s topical and diabetic wound scope and from dependent “one step” workflow limitations.

Biosimilar vs. formulation competition

If competitors use the same anakinra sequence: they remain vulnerable to infringement theories on the gel method if their product is used as claimed.
If competitors shift to different proteins: they can potentially avoid the sequence limitation but may lose clinical alignment and regulatory approval differentiation.

Manufacturing/IP barriers

Even where excipients can be changed, biologic stability in topical gels and consistent delivery to wound sites can require process development that creates trade secret and process patent exposure beyond the scope of US 10,478,394.

Key Takeaways

US 10,478,394 claims a topical, wound-directed method in diabetic chronic wounds using an anakinra therapeutic protein defined by SEQ ID NO: 26, formulated as a gel.
Dependent claims add enforceable narrowing: diabetic ulcer, topical administration, and wound dressing integration, including a potentially critical “one step” workflow limitation and adhesive bandage.
Claim 7 creates additional overlap and litigation leverage by explicitly adding platelet-derived growth factor and/or becaplermin.
Practical infringement and design-around hinge on (1) protein sequence identity under “consisting of,” (2) whether the product is legally a “gel” administered to the wound, (3) whether the workflow matches the dressing limitations.

FAQs

Does US 10,478,394 cover systemic anakinra therapy for diabetic ulcers?
No coverage is created by the claim language provided because the method requires administration to the chronic wound, and dependent Claim 3 requires topical administration.
Can a competitor avoid infringement by changing the gel excipients while keeping anakinra (SEQ ID NO: 26)?
The claim excerpt does not restrict excipients, so excipient changes alone are unlikely to avoid the “gel comprising” and “therapeutic protein consisting of SEQ ID NO: 26” limitations.
Is “applying a wound dressing” required for infringement of Claim 1?
No. Claim 1 does not require a dressing; Claims 4-6 add that as limitations.
How can a competitor design around the “one step” administration and dressing step?
By structuring the commercial product and clinical protocol so that administration and dressing application are not “achieved in one step,” as construed under claim interpretation.
Would combination therapy with becaplermin automatically infringe Claim 7?
It can, if the remaining elements of Claim 7 are met, including use of the claimed anakinra gel method for the diabetic chronic wound and the adjunct regimen.

References

No external sources were cited because no publication bibliographic data, family members, Orange Book listing records, or litigation/PTAB materials for US 10,478,394 were provided in the prompt.

Title:	Compositions and methods to promote wound healing
Abstract:	The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.
Inventor(s):	Yu; Fu-Shin X. (Troy, MI)
Assignee:	Wayne State University (Detroit, MI)
Application Number:	15/557,407
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 10,478,394: What Does It Claim for Topical Anakinra Gel Methods in Diabetic Chronic Wounds, and How Strong Is the U.S. Patent Estate? Executive summary: US 10,478,394 is a method claim set aimed at topical, wound-facing delivery of an anakinra (therapeutic protein, SEQ ID NO: 26) gel to promote healing of chronic wounds in diabetic subjects, with narrower dependent claims for diabetic ulcers, topical application, and dressing workflows. The patent landscape around it in the U.S. splits into (1) earlier anakinra formulation and topical delivery claims, (2) diabetic wound and inflammation-based biologic gel/biomaterial claims, (3) growth factor adjunct method claims (platelet-derived growth factor and becaplermin), and (4) generic and biosimilar freedom-to-operate risks driven by whether the claimed “gel comprising anakinra consisting of SEQ ID NO: 26” and the one-step dressing workflow are meaningfully differentiating. The core infringement risk hinges on sequencing fidelity (SEQ ID NO: 26), the “consisting of” protein boundary, and whether a competing gel is a gel “administered to the chronic wound” as claimed, rather than systemically delivered or delivered through a device that changes the treatment “one step” characterization. What patents protect topical anakinra gel methods for diabetic chronic wound healing in the U.S.? Short answer: The protection centers on method-of-treatment using topical anakinra as the active therapeutic protein in a gel to heal chronic diabetic wounds. The strongest claim leverage is Claim 1’s requirement that the gel includes a therapeutic protein “consisting of the sequence provided in SEQ ID NO: 26 (anakinra),” and that the administration is to the chronic wound in a diabetic subject. Dependent claims tighten the wound type (diabetic ulcer), administration modality (topical), and workflow (wound dressing applied, including adhesive bandage and “achieved in one step”). Claim scope and enforceability signals in US 10,478,394 Active ingredient boundary: Claim 1 uses a “therapeutic agent consisting of a therapeutic protein consisting of SEQ ID NO: 26 (anakinra).” Two “consisting of” boundaries usually aim to exclude: proteins not matching SEQ ID NO: 26, and therapeutic agents that are not limited to the protein described, depending on how the transition language is construed. Route and target: The claim requires administration “to the chronic wound.” This supports direct infringement theories for products designed for topical wound contact rather than systemic use. Disease and indication nexus: “Chronic wound in a diabetic subject” narrows the patient population and supports method claim enforceability when evidence shows diabetic status. Biological mechanism breadth is not required: While anakinra is an IL-1 pathway blocker, the claim does not require a specific mechanistic biomarker. The proof burden typically shifts to wound-healing outcomes and administration practices. How broad are the dependent claims? Claim 2 (diabetic ulcer): narrows from any diabetic chronic wound to diabetic ulcer. If a competitor targets diabetic foot ulcer specifically, Claim 2 can still be implicated, but if it targets another diabetic chronic wound phenotype, only Claim 1 may be asserted. Claim 3 (topically administering): sets route specificity. If a competing product is delivered via an implant or device but still results in topical administration to the wound, the legal question becomes whether it is “topical administering” in claim construction. Claims 4-6 (wound dressing, adhesive bandage, one-step): adds product-workflow features that can be strong differentiators. Many commercial wound-care workflows use gels plus dressings. The critical question is whether competing “one-step” systems are marketed and used as a single integrated application, or as sequential steps. Claim 7 (adjunct growth factor therapy) Claim 7 adds method combinations with platelet-derived growth factor and/or becaplermin. This expands infringement theory for clinicians using anakinra gel plus these adjuncts. It also raises design-around options: a competitor could avoid combination therapy patterns, but that does not avoid Claim 1 unless the adjunct element becomes a required limitation for infringement of Claim 7. When does US Patent 10,478,394 lose exclusivity in the U.S., and what does that mean for generic entry timing? Short answer: The enforceable term of a U.S. utility patent runs 20 years from the earliest effective non-provisional filing date, adjusted for Patent Term Adjustment (PTA) and any Patent Term Extension (PTE) if applicable (none is typical for method-of-use topical biologic gel patents). The key decision point for generic or biosimilar entry is whether the product would infringe claims during the life of the patent or whether it can launch with design-around before expiration. Where timeline risk typically concentrates for patents like this Biosimilar/generic entry to topical anakinra: Anakinra itself is an approved biologic drug substance (elsewhere marketed for systemic use). For wound-healing topical gels, the regulatory and commercial path may be an NDA or 505(b)(2) using a known biologic active. Even if FDA approval exists, patent expiration drives enforceability. Filing-to-expiration uncertainty: Without the patent’s priority data and PTA/PT extension figures, an exact expiration date cannot be stated from the claim text alone. What matters operationally is that patent life is usually shorter than the typical commercial cycle for diabetic wound products and adjunct combination regimens. Actionable timing lens If a competitor files an early development pathway (e.g., reformulation to avoid “consisting of SEQ ID NO: 26” constraints or to recharacterize delivery as a different device application), it may not need to wait for the patent to expire. If a competitor uses anakinra (identical sequence) in a wound gel with comparable topical delivery, the timing analysis becomes a question of design-around vs. waiting for expiration. What claim elements are most likely to be litigated in infringement under US 10,478,394? Short answer: The likely litigation focal points are (1) whether the therapeutic protein matches SEQ ID NO: 26 under a “consisting of” construction, (2) whether the product is a “gel” administered “to the chronic wound,” (3) whether the administration is “topical,” and (4) whether the dressing workflow meets the “one step” limitation in Claims 5-6. Protein sequence boundary: SEQ ID NO: 26 and “consisting of” Direct infringement theory: A plaintiff can argue that a competitor’s protein matches anakinra’s sequence (SEQ ID NO: 26) and that the product contains anakinra as the therapeutic agent consistent with the claim’s “consisting of” language. Defense theory: A defendant may argue that its protein is not within the claim because it includes additional therapeutic agents or modifications that are argued to fall outside “consisting of” the specified therapeutic protein. The practical battleground often becomes analytical characterization of the therapeutic protein and formulation composition. “Gel comprising” vs. device-mediated delivery Many wound-care products use: a gel as a carrier, an alginate or hydrocolloid dressing, an adhesive bandage interface. The question is whether the commercial product is, in claim terms, a “gel” administered to the chronic wound, not merely a dressing that includes a coating or loading. “One step” application workflow If a competitor sells a kit used in two separate application events (apply gel, then apply dressing), it may argue non-infringement of Claim 5. Claim 4’s broader “further comprising applying a wound dressing” is easier to meet than Claim 5’s narrower “administering and applying are achieved in one step.” Which companies are challenging patents like US 10,478,394 in diabetic wound biologic delivery, and how do Paragraph IV-type risks differ for method claims? Short answer: Method claims like these are typically asserted through patent litigation against product launch rather than Orange Book Paragraph IV certification dynamics unless the patent is listed in the Orange Book for an FDA-approved drug with the claimed method. The business risk is still “launch risk,” but the procedural mechanism may be declaratory judgment, injunctive action, or settlement conditioned on non-infringing labeling and marketing. Why Orange Book Paragraph IV is often less direct for this fact pattern US 10,478,394 is a method claim anchored to therapeutic use and topical administration. Orange Book listing is often limited to patents that claim the drug product or use. If the patent is not listed for a specific FDA reference listed drug (RLD) or for the specific approved product, the Paragraph IV framework may not apply cleanly. Even if Orange Book-listed, method claims can be asserted against labeling and promotional instructions, not only the dosage form. Practical litigation posture A typical defendant strategy is to argue non-infringement by: using a different protein sequence, using a different delivery system not described as “gel,” avoiding the “one step” dressing workflow, limiting indications such that diabetic ulcers are not the labeled use, while still using off-label in the real world. A typical plaintiff strategy is to focus on evidence of actual use in the claimed patient population and administration modality, plus product composition and labeling that encourages the claimed method. (No company-specific challenge list can be provided from the claim text alone. Company names require patent numbers, litigation dockets, or Orange Book listing data.) What is the Orange Book status of US 10,478,394, and does that affect enforceability for gel-based anakinra wound therapies? Short answer: Orange Book status is determinative of whether FDA submission certifications and regulatory triggers map to this patent, but claim enforceability itself exists regardless of listing once jurisdiction and infringement proof are established. How Orange Book listing typically changes the business playbook If listed as a method-of-use patent: it can create launch leverage via certification disputes, often accelerating settlement timelines. If not listed: enforcement shifts to civil patent litigation timelines and potential state law or federal Lanham Act labeling disputes, depending on marketing facts. (Orange Book listing status cannot be stated from the claim text alone.) How strong is the patent estate for anakinra in wound-healing gel formulations around US 10,478,394? Short answer: The strength is claim-construction dependent. The combination of “consisting of” protein sequence limitation plus topical administration and dressing workflow can create a narrower but higher-specificity scope. Strength is reduced if competitors can plausibly show that their therapeutic protein formulation deviates from SEQ ID NO: 26 boundaries or that their delivery is not a gel or not administered as claimed. Estate strength drivers Whether there are complementary claims in the same family (composition of matter, formulation, manufacturing methods, kit systems). Whether other families cover: topical anakinra gel composition ranges and excipients, anakinra stabilization in topical gel matrices, wound dressing-loaded biologic systems. Whether dependent claims create fallback positions that still capture close variants (e.g., dressing applied but not “one step”). Key design-around pressure points Reformulate to change the protein agent from SEQ ID NO: 26 to a different IL-1 inhibitor or engineered analog outside the sequence. Deliver via a device or dressing that is argued not to be a “gel administered to the chronic wound.” Use a clinical workflow that is marketed and used as sequential application, not “one step.” What formulations are protected by US 10,478,394, and what excipient or carrier substitutions are likely non-infringing? Short answer: The independent claim requires a gel “comprising” an anakinra protein with the specified sequence. The claim text does not recite specific excipients. That means many excipient swaps likely remain within the “gel comprising” limitation so long as the therapeutic agent limitation is met. Likely scope of “gel” Because “gel” is not defined in the claim excerpt, courts typically construe it in view of the specification and ordinary meaning. A competitor can attempt to avoid “gel” by using: a liquid solution applied to the wound, a non-gel particulate matrix, a dressing with release from a scaffold that is argued to be not a gel carrier. Therapeutic protein “consisting of” is more constraining than excipients Even if excipients change, the sequence-specific protein requirement is the most likely gatekeeper. If a competitor uses identical anakinra sequence, excipient changes may not provide a safe harbor. What method-of-use patents in diabetic wound biologic delivery could overlap US 10,478,394? Short answer: Overlap risk is typically highest for method-of-treatment patents that combine: diabetic chronic wound indication, topical delivery of anakinra or an IL-1 axis inhibitor, wound dressing adjunct steps, and sometimes combination with growth factors like becaplermin or PDGF. Why Claim 7 broadens overlap Claim 7 explicitly references adding platelet-derived growth factor and/or becaplermin. This is a direct invitation to method overlap arguments in litigation where clinicians or product instructions use those adjuncts. What overlaps don’t capture If another patent covers systemic delivery, or uses a different therapeutic protein (even if functionally similar), it may not overlap on claim elements. Non-matching “sequence” boundaries are often dispositive for proteins where “consisting of” appears. How does US 10,478,394 compare with prior and adjacent patent strategies for chronic diabetic wound healing? Short answer: US 10,478,394 is closer to “specific topical protein-in-gel therapy” than to platform claims covering general wound gels without specific biologics or without the diabetic-specific method anchor. Comparison categories General diabetic wound gels without a specific therapeutic protein sequence: often broader but less enforceable against biologic sequence-targeted competitors. Device-based biologic delivery (sprays, scaffolds, membranes): may avoid “gel” but risk capture if the device results in gel administration to the wound. General IL-1 inhibitor use in wounds: may overlap if it includes diabetic chronic wounds and topical administration with anakinra. Combination therapy patents: likely overlap due to Claim 7’s explicit adjunct references. What patent litigation affects US 10,478,394 and related anakinra wound gel claims? Short answer: Litigation status and docket-level facts cannot be stated from the claim text alone. Litigation risk is normally evaluated by checking: federal district court filings mentioning the patent number, PTAB inter partes review or post-grant review challenging validity, and whether settlements include label or product-use restrictions. (No litigation dossier references can be produced from the information provided.) What generic entry risks exist for topical anakinra gels after US 10,478,394, and what design barriers protect the niche? Short answer: “Generic entry” for a biologic protein is more accurately framed as: biosimilar-like risks for the therapeutic protein component (sequence-identical anakinra), and follow-on competition for the gel formulation and delivery/dressing workflow. The largest barrier is whether competitors can meet the claim’s specific therapeutic protein sequence requirement and still launch a gel that infringes. A meaningful design barrier also comes from the method’s topical and diabetic wound scope and from dependent “one step” workflow limitations. Biosimilar vs. formulation competition If competitors use the same anakinra sequence: they remain vulnerable to infringement theories on the gel method if their product is used as claimed. If competitors shift to different proteins: they can potentially avoid the sequence limitation but may lose clinical alignment and regulatory approval differentiation. Manufacturing/IP barriers Even where excipients can be changed, biologic stability in topical gels and consistent delivery to wound sites can require process development that creates trade secret and process patent exposure beyond the scope of US 10,478,394. Key Takeaways US 10,478,394 claims a topical, wound-directed method in diabetic chronic wounds using an anakinra therapeutic protein defined by SEQ ID NO: 26, formulated as a gel. Dependent claims add enforceable narrowing: diabetic ulcer, topical administration, and wound dressing integration, including a potentially critical “one step” workflow limitation and adhesive bandage. Claim 7 creates additional overlap and litigation leverage by explicitly adding platelet-derived growth factor and/or becaplermin. Practical infringement and design-around hinge on (1) protein sequence identity under “consisting of,” (2) whether the product is legally a “gel” administered to the wound, (3) whether the workflow matches the dressing limitations. FAQs Does US 10,478,394 cover systemic anakinra therapy for diabetic ulcers? No coverage is created by the claim language provided because the method requires administration to the chronic wound, and dependent Claim 3 requires topical administration. Can a competitor avoid infringement by changing the gel excipients while keeping anakinra (SEQ ID NO: 26)? The claim excerpt does not restrict excipients, so excipient changes alone are unlikely to avoid the “gel comprising” and “therapeutic protein consisting of SEQ ID NO: 26” limitations. Is “applying a wound dressing” required for infringement of Claim 1? No. Claim 1 does not require a dressing; Claims 4-6 add that as limitations. How can a competitor design around the “one step” administration and dressing step? By structuring the commercial product and clinical protocol so that administration and dressing application are not “achieved in one step,” as construed under claim interpretation. Would combination therapy with becaplermin automatically infringe Claim 7? It can, if the remaining elements of Claim 7 are met, including use of the claimed anakinra gel method for the diabetic chronic wound and the adjunct regimen. References No external sources were cited because no publication bibliographic data, family members, Orange Book listing records, or litigation/PTAB materials for US 10,478,394 were provided in the prompt. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	December 16, 1997	⤷ Start Trial	2036-03-10
Lynch Regenerative Medicine, Llc	REGRANEX	becaplermin	Gel	103691	16-Dec-97	⤷ Start Trial	2036-03-10
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	14-Nov-01	⤷ Start Trial	2036-03-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,478,394

Summary for Patent: 10,478,394